CO-TERUMO-BCT
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced the opening of its new 91,440-square-meter facility near Ho Chi Minh City, Vietnam. The $100 million manufacturing facility supports the expansion of Terumo BCT’s business globally. When manufacturing operations begin in early 2015, the new manufacturing facility will provide increased production capacity.
Key Facts:
- Terumo BCT is a global medical device manufacturer headquartered in Lakewood, Colorado
- Regional headquarters are in: Brussels, Buenos Aires, Hong Kong and Tokyo
- With a $100M investment, Terumo BCT has built a 91,440-square-meter facility located near Ho Chi Minh City on an area of 10 hectares
- Once fully staffed, the building is expected to accommodate more than 900 new associates
- With the opening of the Vietnam facility Terumo BCT products will be manufactured in seven countries: Belgium, China, India, Japan, Northern Ireland, the United States and Vietnam
- Whole blood bags and disposables for automated collections will be manufactured in Vietnam
- Terumo BCT currently has more than 4,800 associates, and serves three primary customer segments in more than 120 countries and territories: Blood Centers, Therapeutic Apheresis and Cell Collections, and Cell Processing
- The Vietnam facility is part of Terumo BCT's broader strategy that includes investments in its existing U.S. manufacturing operations at its global headquarters in Colorado, and in its manufacturing facilities in Northern Ireland and India
Key Quotes:
Craig Rinehardt, Executive Vice President, Global Operations, Terumo BCT
“This completion of this manufacturing facility represents a continued commitment to our customers on every continent, by providing global capacity and advancing manufacturing techniques that will be used in Vietnam to increase product speed to market and enhance our ability to meet customers’ needs.”
“In less than a year we have broken ground, built and completed construction. With the help of so many, we have brought this investment to life and are thrilled to be opening our doors to the manufacturing facility in Vietnam, a welcome addition to our U.S. manufacturing headquarters, and to our global operations.”
Yutaro Shintaku, President and Representative Director, Terumo Corporation
“Terumo BCT’s new Vietnam facility is the most recent example of how Terumo Corporation is investing in its capabilities globally and the opening of this facility is an exciting new step for us. We are optimistic about the opportunities this new facility provides for us to participate in the region’s growth and live our mission of contributing to society through healthcare.”
Key Resources:
- Vietnam 2014 Facility Photos
- Vietnam 2013 Groundbreaking
- Terumo BCT Colorado Investment
- Terumo BCT Northern Ireland Investment
About Terumo BCT:
Terumo BCT , a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140717006181/en/
Contact:
Terumo BCT
Laura Fusco, +1-303-205-2546
Global
Corporate Communications
press@terumobct.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
AB InBev Reports First Quarter 2025 Results8.5.2025 07:03:00 CEST | Press release
Solid start to the year with EBITDA growth at the top-end of our outlook, continued margin expansion and high-single digit Underlying EPS growth Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3%
Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation7.5.2025 18:55:00 CEST | Press release
Pharmaceutical manufacturer layers ServiceNow over its existing SAP ECC 6 ERP platform, enables intelligent workflow and automation for immediate business impact and avoids low ROI spend on expensive, risky vendor-mandated migration to SAP S/4HANA Knowledge 2025 —Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today at ServiceNow’s annual customer and partner event, Knowledge 2025, announced that Apsen Farmacêutica, a Brazilian pharmaceutical manufacturer, has partnered with Rimini Street and ServiceNow to implement a next-generation vision of enterprise-wide workflow automation. This new vision will enable autonomy across the company to help respond faster to market changes, reduce information silos and improve operational efficiency. This press release features multimedia. View the full release here: https://www.busine
Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials7.5.2025 18:07:00 CEST | Press release
Study conducted by VirTus Respiratory Research demonstrated that vapendavir has potent antiviral activity and improves symptoms in participants with COPD infected with rhinovirus VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507489716/en/ Professor Sebastian Johnston https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vapendavir-results-from-phase-2-placebo-controlled-rhinovirus-challenge-study-in-copd-patients-302448650.html Rhinovirus infection is the cause of at least half of the acute respiratory deteriorat
FlightSafety International Announces Major Expansion at Farnborough Airport7.5.2025 17:56:00 CEST | Press release
FlightSafety International (FSI), a global leader in aviation training, is pleased to announce the expansion of its facilities at Farnborough Airport, the home of British aviation and Europe’s leading airport for premium air travel connectivity, highlighting its commitment to enhancing aviation safety and training excellence in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506583636/en/ Rendering: arriving at FlightSafety International The new FSI centre is expected to open in the second quarter of 2027. Lease terms have been finalised and the planning application was submitted in January. Construction is scheduled to start in late 2025 and finish by early 2027. FSI has operated a training centre at Farnborough Airport since 2004. The new facilities will boost training capacity by 40-50%, enabling more aviation professionals access to FSI's world-class training programmes. The current facility is 4,680 square met
Verimatrix Positioned as a Leader and Ace Performer in the 2025 SPARK MatrixTM for In-App Protection by QKS Group7.5.2025 17:45:00 CEST | Press release
The QKS Group SPARK Matrix™ provides competitive analysis and ranking of the leading In-App Protection vendors.Verimatrix is recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™.Verimatrix has also been named an Ace Performer – a recognition given to vendors that demonstrate revenue growth potential, partnership strategy, and customer acquisition – all evaluated over the last one-year period or since the previous SPARK Matrix™ assessment. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507970501/en/ Verimatrix positioned as a Leader in the 2025 SPARK Matrix™ for In-App Protection by QKS Group. Verimatrix has been recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™. The compan
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum